## FORM 4

Check this box if no longer subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-028								
Estimated average burden								
hours per response:	. 0.5							

to Section 16. Fo obligations may of Instruction 1(b).		Filed	pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940			Estimated average burden hours per response:		0.5
1. Name and Address of Reporting Person <sup>*</sup> Lapuerta Pablo			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>LEXICON PHARMACEUTICALS, INC.</u> [LXRX]		tionship of F all applicab Director Officer (giv below)	10% Owne		
(Last) (First) (Middle) 8800 TECHNOLOGY FOREST PLACE			3. Date of Earliest Transaction (Month/Day/Year) 04/22/2020	EVP and CMO				
(Street) THE			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	idual or Join	t/Group Filing (	Check Applic	able
WOODLANDS	TX	77381		Х	Form filed	by One Report	ing Person	
					Form filed Person	by More than C	One Reporting	3
(City)	(State)	(Zip)						

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	04/22/2020		A <sup>(1)</sup>		19,893	Α	\$ <b>0</b>	92,532	D	
Common Stock	04/22/2020		<b>F</b> <sup>(2)</sup>		6,813	D	\$1.96	85,719	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deriv Secu Acqu (A) of Dispo of (D) (Instr	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date Amount of			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

**Explanation of Responses:** 

1. Issued upon vesting of performance-based restricted stock units granted on December 5, 2019, the vesting of which was determined by the compensation committee in its sole discretion based on prespecified corporate goals.

2. Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.

## /s/ Pablo Lapuerta, M.D.

04/24/2020 Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.